You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 20, 2024

Investigational Drug Information for ALXN2050


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug ALXN2050?

ALXN2050 is an investigational drug.

There have been 17 clinical trials for ALXN2050. The most recent clinical trial was a Phase 1 trial, which was initiated on December 16th 2019.

The most common disease conditions in clinical trials are Glomerulonephritis, IGA, Renal Insufficiency, and Myasthenia Gravis. The leading clinical trial sponsors are Alexion Pharmaceuticals, Celerion, and Achillion, a wholly owned subsidiary of Alexion.

There are three US patents protecting this investigational drug and thirty-three international patents.

Recent Clinical Trials for ALXN2050
TitleSponsorPhase
Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and CarbamazepineAlexion Pharmaceuticals, Inc.Phase 1
A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult ParticipantsAlexionPhase 1
Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 PharmacokineticsParexelPhase 1

See all ALXN2050 clinical trials

Clinical Trial Summary for ALXN2050

Top disease conditions for ALXN2050
Top clinical trial sponsors for ALXN2050

See all ALXN2050 clinical trials

US Patents for ALXN2050

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ALXN2050 ⤷  Sign Up Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders Achillion Pharmaceuticals, Inc. (New Haven, CT) ⤷  Sign Up
ALXN2050 ⤷  Sign Up Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders Achillion Pharmaceuticals, Inc. (New Haven, CT) ⤷  Sign Up
ALXN2050 ⤷  Sign Up Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders Achillion Pharmaceuticals, Inc. (New Haven, CT) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ALXN2050

Drugname Country Document Number Estimated Expiration Related US Patent
ALXN2050 Argentina AR106018 2035-08-26 ⤷  Sign Up
ALXN2050 Australia AU2016311425 2035-08-26 ⤷  Sign Up
ALXN2050 Australia AU2021202728 2035-08-26 ⤷  Sign Up
ALXN2050 Canada CA2996415 2035-08-26 ⤷  Sign Up
ALXN2050 China CN108024992 2035-08-26 ⤷  Sign Up
ALXN2050 China CN114044800 2035-08-26 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.